Display Settings:

Format

Send to:

Choose Destination
See comment in PubMed Commons below
J Ocul Pharmacol Ther. 2010 Aug;26(4):373-9. doi: 10.1089/jop.2010.0030.

Efficacy and tolerability of imiquimod 5% cream to treat periocular basal cell carcinomas.

Author information

  • 1Ophthalmology Department, Miguel Servet Universitary Hospital, Zaragoza, Spain. egmvivax@yahoo.com

Abstract

PURPOSE:

To assess the efficacy and safety of nonsurgical treatment with imiquimod (IMQ) 5% cream in patients with periocular nodular basal cell carcinoma (BCC).

METHODS:

Fifteen patients with clinical and histopathological diagnosis of nodular BCC on the eyelid were treated with IMQ 5% cream once daily, 5 days/week for 6 weeks. Three patients had tumor persistence after photodynamic therapy and 1 patient had failed cryotherapy.

RESULTS:

All tumors showed histopathological remission within 3 months of starting IMQ, and sustained clinical remission was documented in each patient after 24-28 months' follow-up. Treatment tolerability was bad in 7 patients with local effects being most problematic, but all symptoms disappeared when treatment ended.

CONCLUSIONS:

IMQ therapy is effective for treating periocular BCCs with a cure rate similar to that of surgery. Aesthetic results were rated as excellent. IMQ is a useful alternative to surgery in patients with periocular BCCs when other therapies have failed or are not possible.

PMID:
20698800
[PubMed - indexed for MEDLINE]
PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for Mary Ann Liebert, Inc.
    Loading ...
    Write to the Help Desk